KS MPJE cheat sheet

Minnesota Board of Pharmacy licenses pharmacies, pharmacists, and pharmacy technicians; technician registration requires Board approval, and certified technicians may perform additional tasks under written protocol.

Minnesota requires pharmacies to maintain a written policy and procedure manual available for Board inspection; the pharmacist-in-charge is responsible for its content, annual review, and staff training documentation.

Patient counseling in Minnesota must be offered by the pharmacist (or intern under supervision) for each new prescription and when the pharmacist deems it warranted; a documented refusal may be recorded in the patient record.

Minnesota prescription drug monitoring program (PMP) reporting: dispensers submit controlled substance dispensing data to the state PMP as required by statute; pharmacists must check the PMP before dispensing certain controlled substances per state law.

Minnesota allows pharmacist prescribing of self-administered hormonal contraceptives, naloxone, and tobacco cessation aids under protocol; specific training, documentation, and notification requirements apply.

Continuous quality improvement (CQI) program: Minnesota pharmacies must maintain a CQI program to track and analyze dispensing errors, with a defined reporting and review process that is not used for disciplinary action against the reporting individual.

Drug take-back and disposal: Minnesota pharmacies may serve as authorized collectors under DEA rules and state law; controlled substance destruction must follow DEA and Board requirements with documented witnessing.

Compounding in Minnesota follows USP <795> and <797> standards adopted by the Board; sterile compounding requires environmental monitoring, designated clean rooms, and trained personnel records.

Intern and technician supervision ratios and duties are set by Board rule; a pharmacist may supervise only the number of interns and technicians permitted, and tasks must be within the delegate's training and legal scope.

DEA registration: a separate registration is required for each principal place of business; registrations are renewable every three years, and a pharmacy must notify DEA of changes in name, address, or control within 30 days.

Controlled substance schedules: Schedule II has high abuse potential with accepted medical use (e.g., oxycodone); Schedule III–V have decreasing abuse potential; Schedule I has no accepted medical use and cannot be prescribed.

Prescription requirements for Schedule II: written, electronic, or emergency oral prescriptions only; oral emergency prescriptions require a written follow-up within 7 days; partial fills permitted under specific conditions with remaining quantity dispensed within 72 hours.

DEA Form 222 (or CSOS) is required to order Schedule I and II substances; Schedule III–V may be ordered on invoices, which must be retained for at least 2 years and kept separate from other records.

Recordkeeping: controlled substance inventories (biennial), dispensing records, and power of attorney documents must be maintained and available for DEA inspection for at least 2 years.

Theft or significant loss of controlled substances must be reported to the DEA field office in writing within one business day of discovery, using DEA Form 106; state reporting may also be required.

Federal labeling: prescription labels must include pharmacy name and address, prescription number, date, patient name, directions, prescriber name, and drug name/strength; auxiliary labeling per USP and state law.

FDCA and DSCSA: drug supply chain security requires transaction information, history, and statements for prescription drugs; pharmacies must verify licensure of trading partners and quarantine suspect product.

HIPAA Privacy Rule permits pharmacist disclosures for treatment, payment, and operations; minimum necessary standard applies, and psychotherapy notes require specific authorization.

Police power: states regulate the practice of pharmacy and the distribution of drugs under their police power; state boards of pharmacy are administrative agencies that adopt rules and adjudicate licensure.

Reciprocity and license transfer: most states allow licensure by reciprocity or score transfer under NABP requirements; the candidate must meet the receiving state's education, examination, and jurisprudence requirements.

Mutual recognition vs. reciprocity: MPJE scores are transferred through NABP; states may require additional state-specific jurisprudence examinations, and licensure is not automatic.

Standard of care: pharmacists owe patients a duty of reasonable care; negligence requires duty, breach, causation, and damages; expert testimony is often required to establish the standard.

Confidentiality: patient prescription records are protected by state law and HIPAA; disclosure without authorization is permitted for lawful purposes such as court orders, public health reporting, and third-party payment.

Mandatory reporting: pharmacists must report suspected impaired practitioners, prescription fraud, and certain adverse events to the appropriate state or federal authority as required by statute.

Drug substitution and therapeutic interchange: generic substitution is permitted when the prescriber does not prohibit it and the substituted product is therapeutically equivalent per FDA Orange Book standards; state law governs patient consent and notification.

Controlled substance scheduling and rescheduling: state schedules must be consistent with federal schedules but may be more restrictive; state boards may add substances to state schedules.

Prescription validity: prescriptions must be issued for a legitimate medical purpose by a practitioner acting in the usual course of professional practice; pharmacists have a corresponding responsibility to resolve red flags before dispensing.

Minnesota pharmacy technician registration: technicians must register with the Board, complete required training, and work under pharmacist supervision; certified technicians may perform additional tasks defined by rule.

Minnesota requires a written policy and procedure manual available for Board inspection; the pharmacist-in-charge is responsible for content, annual review, and staff training documentation.

Patient counseling must be offered by the pharmacist or supervised intern for each new prescription and when warranted; a documented refusal may be recorded in the patient record.

Minnesota PMP: dispensers report controlled substance dispensing data to the state PMP; pharmacists must check the PMP before dispensing certain controlled substances as required by state law.

Minnesota allows pharmacist prescribing of self-administered hormonal contraceptives, naloxone, and tobacco cessation aids under protocol; specific training, documentation, and notification requirements apply.

Minnesota pharmacies must maintain a continuous quality improvement (CQI) program to track and analyze dispensing errors, with a defined reporting and review process.

Minnesota pharmacies may serve as authorized collectors for drug take-back under DEA rules and state law; controlled substance destruction must follow DEA and Board requirements with documented witnessing.

Compounding follows USP <795> and <797> standards adopted by the Board; sterile compounding requires environmental monitoring, designated clean rooms, and trained personnel records.

Intern and technician supervision ratios and duties are set by Board rule; tasks must be within the delegate's training and legal scope.

DEA registration: separate registration required for each principal place of business; renewable every three years, and a pharmacy must notify DEA of changes in name, address, or control within 30 days.

Controlled substance schedules: Schedule II has high abuse potential with accepted medical use; Schedule III–V have decreasing abuse potential; Schedule I has no accepted medical use and cannot be prescribed.

Schedule II prescriptions: written, electronic, or emergency oral only; oral emergency prescriptions require written follow-up within 7 days; partial fills permitted under specific conditions with remaining quantity dispensed within 72 hours.

DEA Form 222 (or CSOS) is required to order Schedule I and II substances; Schedule III–V may be ordered on invoices, which must be retained at least 2 years and kept separate from other records.

Recordkeeping: controlled substance inventories (biennial), dispensing records, and power of attorney documents must be maintained and available for DEA inspection for at least 2 years.

Theft or significant loss of controlled substances must be reported to the DEA field office in writing within one business day of discovery, using DEA Form 106; state reporting may also be required.

Federal labeling: prescription labels must include pharmacy name and address, prescription number, date, patient name, directions, prescriber name, and drug name/strength; auxiliary labeling per USP and state law.

FDCA and DSCSA: drug supply chain security requires transaction information, history, and statements for prescription drugs; pharmacies must verify licensure of trading partners and quarantine suspect product.

HIPAA Privacy Rule permits pharmacist disclosures for treatment, payment, and operations; minimum necessary standard applies, and psychotherapy notes require specific authorization.

Police power: states regulate the practice of pharmacy and distribution of drugs under their police power; state boards of pharmacy are administrative agencies that adopt rules and adjudicate licensure.

Reciprocity and license transfer: most states allow licensure by reciprocity or score transfer under NABP requirements; the candidate must meet the receiving state's education, examination, and jurisprudence requirements.

Mutual recognition vs. reciprocity: MPJE scores are transferred through NABP; states may require additional state-specific jurisprudence examinations, and licensure is not automatic.

Standard of care: pharmacists owe patients a duty of reasonable care; negligence requires duty, breach, causation, and damages; expert testimony is often required to establish the standard.

Confidentiality: patient prescription records are protected by state law and HIPAA; disclosure without authorization is permitted for lawful purposes such as court orders, public health reporting, and third-party payment.

Mandatory reporting: pharmacists must report suspected impaired practitioners, prescription fraud, and certain adverse events to the appropriate state or federal authority as required by statute.

Drug substitution and therapeutic interchange: generic substitution is permitted when the prescriber does not prohibit it and the substituted product is therapeutically equivalent per FDA Orange Book standards; state law governs patient consent and notification.

Controlled substance scheduling and rescheduling: state schedules must be consistent with federal schedules but may be more restrictive; state boards may add substances to state schedules.

Prescription validity: prescriptions must be issued for a legitimate medical purpose by a practitioner acting in the usual course of professional practice; pharmacists have a corresponding responsibility to resolve red flags before dispensing.